ondansetron has been researched along with Coronary Disease in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayindir, O | 1 |
| Güden, M | 1 |
| Akpinar, B | 1 |
| Sanisoğlu, I | 1 |
| Sağbaş, E | 1 |
1 other study available for ondansetron and Coronary Disease
| Article | Year |
|---|---|
Ondansetron hydrochloride for the treatment of delirium after coronary artery surgery.
Topics: Cardiopulmonary Bypass; Coronary Care Units; Coronary Disease; Coronary Vessels; Delirium; Female; H | 2001 |